Real-world clinical experience of ticagrelor in Indian patients with acute coronary syndrome after discharge from a tertiary setting

Authors

  • Dharmendra Jain Department of Cardiology, Institute of Medical Sciences and associated S. S. Hospital, Varanasi, Uttar Pradesh, India
  • Sanjeeb Roy Department of Cardiology, Manglamplus Medicity Hospital, Mansarovar, Jaipur, Rajasthan, India
  • Baskaran Srinivasan Department of Cardiology, Shri Venkateswara Medical College and Research Center, Puducherry, India
  • Sunil Kumar Department of Cardiology, Dana Shivam Heart and Superspeciality Hospital, Jaipur, Rajasthan, India
  • Shaijesh Wankhede Department of Medical Services, USV Pharma Pvt. Ltd., Mumbai, Maharashtra, India
  • Santosh Revankar Scientific Services, USV Private Limited, Mumbai
  • Ashish Birla Department of Medical Services, USV Pharma Pvt. Ltd., Mumbai, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20232090

Keywords:

ACS, Anti-platelet, Intervention, Ticagrelor

Abstract

Background: To understand the usage pattern of ticagrelor in real-life clinical experience in Indian patients with the acute coronary syndrome (ACS) after discharge from a tertiary care setting.

Methods: A retrospective multicentric observational study conducted across Indian healthcare centers having medical records of adult patients with ACS. Patients prescribed with ticagrelor post-discharge for at least 1 month were included. The study endpoints were to determine the clinical effectiveness of ticagrelor in post-ACS patients and adverse events reported during the study period.

Results: A total of 1910 patients with ACS with a mean (SD) age of 58.2 (11.3) years were enrolled in this study. The median (IQR) duration of treatment was 30.0 (30.0-90.0) days. More than half of the patients (n=1115, 58.4%) were managed with interventional therapy. The most common comorbid conditions were type-2 diabetes mellitus (46.9%), followed by hypertension (36.8%). A total of 9.7% of patients reported complaints after treatment with ticagrelor. Among them, weakness, giddiness, and body pain were the most common (3.2%).

Conclusions: This real-world study revealed that ticagrelor had been used widely in patients who underwent different management strategies. History of diabetes and hypertension were the most common risk factors. There were no major adverse events reported during the follow-up, indicating ticagrelor is well-tolerated in Indian patients with ACS.

References

Xavier D, Pais P, Devereaux PJ, Xie C, Prabhakaran D, Reddy KS, et al. CREATE registry investigators. Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet. 2008;371(9622):1435-42.

Gupta R, Gaur K. Acute coronary syndrome. Chapter Epidemiology of acute coronary syndromes in India. CRC press; 2020:11.

Kolansky DM. Acute coronary syndromes: morbidity, mortality, and pharmacoeconomic burden. Am J Manag Care. 2009;15(2 Suppl):S36-41.

Kumar A, Cannon CP. Acute coronary syndromes: diagnosis and management, part I. Mayo Clin Proc. 2009;84(10):917-38.

Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-57.

Bonaca MP, Goto S, Bhatt DL, Steg PG, Storey RF, Cohen M, et al. Prevention of stroke with ticagrelor in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54 (prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin-thrombolysis in myocardial infarction 54). Circulation. 2016;134(12):861-71.

Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77.

Collet JP, Thiele H. The 'Ten Commandments' for the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020;41(37):3495-7.

Central Drugs Standard Control Organization. List of Approved Drugs from 01-01-2012 to till Date; 2012. Available at: http://cdsco.nic.in/ APD-DRUG-2012(1).pdf. Accessed on 15 November 2022.

You SC, Rho Y, Bikdeli B, Kim J, Siapos A, Weaver J, et al. Association of ticagrelor vs clopidogrel with net adverse clinical events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. JAMA. 2020;324(16):1640-50.

Vercellino M, Sànchez FA, Boasi V, Perri D, Tacchi C, Secco GG, et al. Ticagrelor versus clopidogrel in real-world patients with ST elevation myocardial infarction: 1-year results by propensity score analysis. BMC Cardiovasc Disord. 2017;17(1):97.

De Filippo O, Cortese M, D´ Ascenzo F, Raposeiras-Roubin S, Abu-Assi E, Kinnaird T, et al. Real-world data of prasugrel vs. ticagrelor in acute myocardial infarction: results from the RENAMI Registry. Am J Cardiovasc Drug. 2019;19(4):381-91.

Sawhney JPS, Dalal J, Mullasari A, Bansal S, Kahali D. Therapeutic experience of ticagrelor in Indian patients with acute coronary syndrome: A non-interventional, prospective, and observational study. Indian Heart J. 2019;71(4):344-9.

Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68(10):1082-115.

Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213-60.

Yudi MB, Clark DJ, Farouque O, Eccleston D, Andrianopoulos N, Duffy SJ, et al. Melbourne Interventional Group. Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Intern Med J. 2016;46(5):559-65.

Sahlen A, Varenhorst C, Lagerqvist B, Renlund H, Wallentin L, James SK, et al. Contemporary use of ticagrelor in patients with acute coronary syndrome: insights from Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). Eur Heart J Cardiovasc Pharmacother. 2016;2(1):5-12.

Piccolo R, Gargiulo G, Franzone A, Santucci A, Ariotti S, Baldo A, et al. Use of the dual-antiplatelet therapy score to guide treatment duration after percutaneous coronary intervention. Ann Intern Med 2017;167(1):17-25.

Assessment report for Brilique. European Medicines Agency. Procedure no. EMEA/H/C/1241/2011. Available at: http://www.ema.europa.eu/docs/ library/EPAR_report/human/001241/WC50010049. Accessed on 16 November 2022.

Product monograph. Brillinta: Ticagrelor tablets. Available at: http://www.astrazeneca.ca. Accessed on 16 November 2022.

Downloads

Published

2023-06-30

How to Cite

Jain, D., Roy, S., Srinivasan, B., Kumar, S., Wankhede, S., Revankar, S., & Birla, A. (2023). Real-world clinical experience of ticagrelor in Indian patients with acute coronary syndrome after discharge from a tertiary setting. International Journal of Research in Medical Sciences, 11(7), 2503–2507. https://doi.org/10.18203/2320-6012.ijrms20232090

Issue

Section

Original Research Articles